# Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

> **NCT04402073** · PHASE2 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 20 (actual)

## Conditions studied

- Medulloblastoma

## Interventions

- **DRUG:** Sonidegib
- **DRUG:** Cisplatin
- **DRUG:** Lomustine
- **DRUG:** Vincristine
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT04402073
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-11
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-09-10
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402073, "Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04402073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*